Clinical Trial Update: Modulation of Abeta Levels by GSK933776 in Alzheimer's Disease Patient [Phase 1]

View source ↗

Summary

A Phase 1 trial assessing modulation of Abeta levels by GSK933776 in patients with Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• GSK933776

Snippet

Sponsor: GlaxoSmithKline | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED